Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 4 ( April, 2021 ) > List of Articles

ORIGINAL RESEARCH

Prevalence of Bloodstream Infections and their Etiology in COVID-19 Patients Admitted in a Tertiary Care Hospital in Jaipur

Ekadashi Rajni, Vishnu K Garg, Daisy Bacchani, Richa Sharma, Rajat Vohra, Vedprakash Mamoria, Hemant Malhotra

Keywords : Antibiotic stewardship, Antimicrobial resistance, Bacteremia, Blood culture, Blood epidemiology, Bloodstream, Coinfections, COVID-19, Sepsis

Citation Information : Rajni E, Garg VK, Bacchani D, Sharma R, Vohra R, Mamoria V, Malhotra H. Prevalence of Bloodstream Infections and their Etiology in COVID-19 Patients Admitted in a Tertiary Care Hospital in Jaipur. Indian J Crit Care Med 2021; 25 (4):369-373.

DOI: 10.5005/jp-journals-10071-23781

License: CC BY-NC 4.0

Published Online: 01-04-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: World is in grip of coronavirus disease-2019 (COVID-19) pandemic right now. Majority of studies center around its epidemiological and clinical characteristics. Information regarding secondary bacterial infections is limited. This retrospective observational study was done to determine the prevalence and characteristics of bloodstream infections in COVID-19 patients admitted in a tertiary care center in Jaipur. Materials and methods: All blood cultures received from COVID-19 positive patients admitted in designated COVID care ICUs and wards were included in the study. A predesigned pretested questionnaire was used to collect relevant data. Blood cultures were done using BD BACTEC™ FX40, and identification and antimicrobial susceptibility testing of isolates were done by VITEK® 2 COMPACT. Results: One thousand five hundred seventy-eight (1578) COVID-19 positive patients were admitted in center during 5-month study period from whom 158 blood cultures were received. Out of these, 15 (9.4%) were positive. Median age of patients with positive blood culture was 54 years and included 10 males and 5 females. Ten (67%) patients needed intensive care in ICU. Significant correlation of blood culture positivity was found with parameters like ICU admission, presence of an indwelling device, underlying comorbidity, raised biochemical markers, and adverse clinical outcome. Conclusions: Incidence of bloodstream infections is low for COVID-19 patients. Antibiotic prophylaxis needs to be used with caution, and prompt discontinuation should be done based on clinical judgment.


PDF Share
  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733. DOI: 10.1056/NEJMoa2001017.
  2. Ranney ML, Griffeth V, Jha AK. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic. N Engl J Med 2020;382:e41. DOI: 10.1056/NEJMp2006141.
  3. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Geneva: World Health Organization; 2020. https://apps.who.int/iris/handle/10665/330893.
  4. Rawson TM, Moore LSP, Zhu N, Nishanthy R, Keira S, Mark G, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clinical Infect Dis 2020;2(1010):1–7. DOI: 10.1093/CID/CIAA530.
  5. Moore SE, Wilde AM, Song M, Bohn BC, Patross CJ, Denham B, et al. A patient with Escherichia coli bacteremia and COVID-19 co-infection: a case report for the Louisville COVID-19 epidemiology study. J Resp Infect 2020;4(1):1–4. DOI: 10.18297/jri/vol4/iss1/15.
  6. Elzein F, Alsherbeeni N, Almatrafi K, Shosha D, Naoufel K. COVID-19 co-infection in a patient with Brucella bacteremia. Respir Med Case Rep 2020;31:1–2. DOI: 10.1016/j.rmcr.2020.101183.
  7. Osakwe N. A case of Bacillus Cereus bacteremia in a COVID-19 patient treated with steroids. IDCases 2020;21:1–2. DOI: 10.1016/j.idcr.2020.e00855.
  8. Anant M, Tiwari P, Bhatnagar S, Ankit P, Abhishek M, Lalit D, et al. Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. Indian J Med Res 2020;152(1):61–69. DOI: 10.4103/ijmr.IJMR_1788_20.
  9. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382: 2372–2374. DOI: 10.1056/NEJMc2010419.
  10. Guan W, Ni Z, Hu Y, Liang W, Qu C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720. DOI: 10.1056/NEJMoa2002032.
  11. Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7(6):1–4. DOI: 10.1093/ofid/ofaa220.
  12. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81(2):266–275. DOI: 10.1016/j.jinf.2020.05.046.
  13. Sepulveda J, Westblade LF, Whittier S, Satlin MJ, Greendyke WG, Aaron JG, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol 2020;58(8):1–7. DOI: 10.1128/JCM.00875-20.
  14. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020;26(10):1395–1399. DOI: 10.1016/j.cmi.2020.06.025.
  15. Kadri SS, Lai YL, Warner S, Strich JK, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2020;21:241–251. DOI: 10.1016/s1473-3099(20)30477-1.
  16. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020;201(11):1380–1388. DOI: 10.1164/rccm.202002-0445OC.
  17. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846–848. DOI: 10.1007/s00134-020-05991-x.
  18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–1062. DOI: 10.1016/s0140-6736(20)30566-3.
  19. Lippi G, Plebani M. Procalcitonin in patients with severe corona- virus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta 2020;505:190–191. DOI: 10.1016/j.cca.2020.03.004.
  20. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center in Wuhan, China. Infect Control Hosp Epidemiol 2020;41(8):1–2. DOI: 10.1017/ice.2020.126.
  21. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110–118. DOI: 10.1016/j.jaci.2020.04.006 S0091-6749(20)30495-4.
  22. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg Infect Dis 2020;26(11):2694–2696. DOI: 10.3201/eid2611.203504.
  23. Alanio A, Dellière S, Fodil S, Bretagne S, Megarbane B. High prevalence of putative invasive pulmonary Aspergillosis in critically ill COVID-19 patients. Lancet Respir Med 2020;8(6):e48–e49. DOI: 10.2139/ssrn.3575581.
  24. Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin AG, Thellier M. Fatal invasive Aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis 2020;26(7):1636–1637. DOI: 10.3201/eid2607. 201603.
  25. World Health Organization. Clinical management of COVID-19: interim guidance. Geneva: World Health Organization; 2020, pp. 1–62. Available from: https://apps.who.int/iris/handle/10665/332196.
  26. Bwire GM. Coronavirus: why men are more vulnerable to Covid-19 than women? SN Compr Clin Med 2020;2:1–3. DOI: 10.1007/s42399-020-00341-w.
  27. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8:1–6. DOI: 10.3389/fpubh.2020.00152/full.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.